- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arovella Therapeutics Ltd (ALA)
Arovella Therapeutics Ltd stock price live, this page displays ASX ALA stock exchange data. View the ALA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arovella Therapeutics Ltd real time stock price chart below.
What Is the Arovella Therapeutics Ltd Stock Price Today?
The Arovella Therapeutics Ltd stock price today is 0.089.
What Is the Stock Symbol for Arovella Therapeutics Ltd?
The stock symbol for Arovella Therapeutics Ltd is ""ALA.""
What Stock Exchange Does Arovella Therapeutics Ltd Trade On?
Arovella Therapeutics Ltd is listed and trades on the Sydney stock exchange.
Is Arovella Therapeutics Ltd a Good Stock to Buy?
Determining whether Arovella Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALA quote. (ISIN: AU0000182784)
What Is the Arovella Therapeutics Ltd Stock Price Today?
The Arovella Therapeutics Ltd stock price today is 0.089.
What Is the Stock Symbol for Arovella Therapeutics Ltd?
The stock symbol for Arovella Therapeutics Ltd is ""ALA.""
What Stock Exchange Does Arovella Therapeutics Ltd Trade On?
Arovella Therapeutics Ltd is listed and trades on the Sydney stock exchange.
Is Arovella Therapeutics Ltd a Good Stock to Buy?
Determining whether Arovella Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALA quote. (ISIN: AU0000182784)
Sydney
Currency in AUD
0.089
+0.005(+5.95%)
Closed·
Fair Value
An estimate of a Arovella Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.085
0.091
52 wk Range
0.068
0.210
ALA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ALA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Arovella Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0850.091
52 wk Range
0.0680.210
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ALA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arovella Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price often moves in the opposite direction of the market
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Arovella Therapeutics Ltd Company Profile
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. Its ALA-101 product entered first-in-human phase 1 clinical trial. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Arovella Therapeutics Ltd Earnings Call Summary for Q3/2025
- Arovella reports $23.5M cash position, bolstered by $15M placement, ensuring funding for LL-101 phase one trials in 2025
- Company aims to file IND for LL-101 by Q2 2024, focusing on innovative iNKT cell therapies for various cancers
- Analyst consensus target of $0.21, with revenue forecasts of $2.12M for FY2025 and $2.45M for FY2026
- CEO emphasizes unique position in iNKT cell therapies and data-driven approach to anti-cancer research
- Potential risks include regulatory hurdles, evolving competitive landscape, and critical need for successful clinical trials
Last Updated: 29/04/2025, 03:02
Read Full TranscriptCompare ALA to Peers and Sector
Metrics to compare | ALA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.3x | −6.9x | −0.6x | |
PEG Ratio | −0.50 | −0.01 | 0.00 | |
Price/Book | 5.0x | 1.7x | 2.6x | |
Price / LTM Sales | 29.0x | 13.0x | 3.3x | |
Upside (Analyst Target) | 292.9% | 186.7% | 38.7% | |
Fair Value Upside | Unlock | 12.0% | 5.1% | Unlock |
Earnings
Latest Release
Aug 21, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
830.00 / --
People Also Watch
FAQ
What Stock Exchange Does Arovella Therapeutics Trade On?
Arovella Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.
What Is the Stock Symbol for Arovella Therapeutics?
The stock symbol for Arovella Therapeutics is "ALA."
What Is the Arovella Therapeutics Market Cap?
As of today, Arovella Therapeutics market cap is 105.87M.
What Is Arovella Therapeutics's Earnings Per Share (TTM)?
The Arovella Therapeutics EPS (TTM) is -0.01.
From a Technical Analysis Perspective, Is ALA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Arovella Therapeutics Stock Split?
Arovella Therapeutics has split 5 times.
How Many Employees Does Arovella Therapeutics Have?
Arovella Therapeutics has 27 employees.
What is the current trading status of Arovella Therapeutics (ALA)?
As of 28 Aug 2025, Arovella Therapeutics (ALA) is trading at a price of 0.09, with a previous close of 0.08. The stock has fluctuated within a day range of 0.09 to 0.09, while its 52-week range spans from 0.07 to 0.21.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.